Full-Time

Senior Scientist 2

ADC Reaction Engineering

Updated on 9/3/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$109.5k - $208.5k/yr

Waukegan, IL, USA

In Person

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • BS, MS, or PhD in Chemical/Bio Engineering or a related field and 12+ (BS), 10+ (MS), or 4+ (PhD) years of relevant industrial experience
  • Demonstrated capability to model antibody drug conjugate kinetics and mechanisms
  • Experience with drug linker and drug substance process design, including tech transfer and scale-up
  • Development of flow chemistry reactor platforms, including in use for ADCs
  • Experience with highly potent compound handling
  • Leadership of novel reactor configuration development (e.g., photochemistry, electrochemistry, membrane reactors, etc.)
  • Expertise in computational fluid dynamics to support reactor design and tech transfer
  • The candidate is expected to demonstrate the ability to solve difficult technical problems and champion new technologies to achieve project goals
  • The candidate is required to be a strong team player and demonstrate scientific leadership, possessing effective oral and written communication skills for facilitating collaborations and leading cross-functional process development teams
  • In addition to technical requirements, the role requires collaboration across cross-functional teams and leadership in matrixed environments
  • Ability to author publications and present at scientific conferences
Responsibilities
  • Develop robust manufacturing processes, supporting assets through all phases of development
  • Participate in and/or lead project teams towards development and characterization of new small and large molecule assets. Establish, communicate, and execute research plans
  • Develop commercial ready manufacturing processes in the laboratory and demonstrate the processes in the pilot plant
  • Set project strategies, define project responsibilities and timelines, and provide leadership in a matrixed team setting
  • Address challenging problems with chemical and biochemical reactions, separations, and/or isolations using demonstrated expertise in reaction kinetics, transport phenomena, and mathematical modeling
  • Develop and apply process analytical technologies and data-rich experimentation tools to build appropriate reaction and process understanding via model-guided experimentation
  • Build data driven and knowledge driven models to facilitate successful scale-up and tech transfer
  • Author and/or review technical documents summarizing process development efforts and contribute to regulatory filings
  • Exhibit a collaborative nature in identifying process challenges on a wide range of projects and communicate findings and recommendations effectively by multi-disciplinary interactions with organic chemists, analytical chemists, process development engineers, pilot plant engineers, drug product development scientists, program managers, and regulatory affairs specialists
  • Author publications and present at scientific conferences

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Etentamig hit 74% response and 60% progression-risk reduction on September 3, 2026.
  • FDA approved Decnupaz on May 27, 2026, creating AbbVie’s first blood-cancer ADC.
  • WCLC 2026 data showed ABBV-1480 and ABBV-706 strength across lung-cancer programs.

What critics are saying

  • Imbruvica sales fell 29.4% in Q2 2026, exposing oncology erosion.
  • FDA declined trenibotE in April 2026; manufacturing fixes pushed approval into 2027.
  • CMS Botox price controls and AbbVie’s February 2026 lawsuit threaten aesthetics margins.

What makes AbbVie unique

  • AbbVie’s 2026 engine combines Skyrizi, Rinvoq, oncology, and aesthetics.
  • Apogee acquisition deepens AbbVie’s inflammatory pipeline beyond Humira replacement products.
  • AbbVie commercializes injectable biologics and ADCs across specialty, outpatient, and hospital settings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Sep 3rd, 2026
AbbVie's etentamig shows 74% response rate in cancer trial, beating standard treatment by 28 percentage points

AbbVie's experimental cancer drug etentamig achieved a 74% overall response rate in a pivotal Phase 3 trial for relapsed or refractory multiple myeloma, significantly outperforming standard treatments at 45.7%. The study also met its progression-free-survival endpoint. The drug remains investigational pending regulatory review. AbbVie's oncology division reported $1.65 billion in second-quarter revenue, down 1.5%, representing roughly 9.7% of total sales. Venclexta grew 11.6%, whilst Imbruvica declined 29.4%. AbbVie shares traded at $260.445. The company requires new growth drivers as its existing oncology portfolio faces mixed performance. Detailed safety and durability data have not yet been disclosed.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Aug 29th, 2026
AbbVie acquires Apogee for $10.9B as Eli Lilly's GLP-1 drugs drive 45% revenue surge

AbbVie is acquiring Apogee Therapeutics for approximately $10.9 billion as it works to diversify beyond its core immunology portfolio. The pharmaceutical giant reported revenue of nearly $61.2 billion in FY 2025, up roughly 8.7% year-on-year, with Skyrizi and Rinvoq accounting for about 42% of sales. Eli Lilly achieved sharper growth, with revenue reaching nearly $65.2 billion in FY 2025, a 45% increase driven by GLP-1 drugs Mounjaro and Zepbound. These therapies represented roughly 56% of total revenue. Net income was approximately $20.6 billion. AbbVie's balance sheet shows a debt-to-equity ratio of negative 21x, whilst Eli Lilly's stands at roughly 1.6x. Free cash flow was nearly $17.8 billion for AbbVie and close to $9.0 billion for Eli Lilly.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 25th, 2026
AbbVie's oncology sales fall 2.4% to $1.65B as Imbruvica drops 29%

AbbVie's oncology revenues declined 2.4% year over year to $1.65 billion in Q2 2026, pressured by blood cancer drug Imbruvica, whose sales fell 29.4% to $532 million due to competitive pressure and IRA-driven pricing changes. However, growth from other products partially offset this decline. Venclexta sales rose nearly 10% to $771 million, driven by strong demand in chronic lymphocytic leukaemia. Newer products showed robust growth, with Elahere up 32% to $211 million and Epkinly increasing 48% to $103 million. Lung cancer therapy Emrelis exceeded expectations as physicians became more familiar with c-Met testing. The quarter also marked the launch of Decnupaz, AbbVie's first marketed antibody drug conjugate in haematology, following recent FDA approval for blastic plasmacytoid dendritic cell neoplasm.